Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 341,117 shares of the specialty pharmaceutical company’s stock after buying an additional 15,078 shares during the period. Principal Financial Group Inc. owned approximately 0.59% of Supernus Pharmaceuticals worth $17,632,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Fifth Third Bancorp grew its holdings in shares of Supernus Pharmaceuticals by 9,598.0% in the 1st quarter. Fifth Third Bancorp now owns 34,137 shares of the specialty pharmaceutical company’s stock worth $1,765,000 after acquiring an additional 33,785 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Supernus Pharmaceuticals during the first quarter worth $212,000. Resona Asset Management Co. Ltd. purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at $504,000. QRG Capital Management Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 14.0% during the first quarter. QRG Capital Management Inc. now owns 10,748 shares of the specialty pharmaceutical company’s stock valued at $556,000 after purchasing an additional 1,318 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd boosted its position in shares of Supernus Pharmaceuticals by 18.1% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 20,236 shares of the specialty pharmaceutical company’s stock valued at $1,046,000 after purchasing an additional 3,096 shares during the period.

Supernus Pharmaceuticals Stock Down 1.9%

SUPN opened at $46.94 on Thursday. The firm has a market capitalization of $2.72 billion, a P/E ratio of -92.04, a PEG ratio of 1.02 and a beta of 0.54. The stock has a fifty day moving average of $46.63 and a 200-day moving average of $49.28. Supernus Pharmaceuticals, Inc. has a 12-month low of $32.51 and a 12-month high of $59.68.

Analysts Set New Price Targets

SUPN has been the topic of a number of analyst reports. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $62.83.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.